Naltrexone Hydrochloride is used as the active pharmaceutical ingredient in the production of both oral and injectable forms of naltrexone. This medication is primarily prescribed for the treatment of alcohol and opioid dependence.
Naltrexone is an opioid receptor antagonist that helps patients discontinue the use of opioids and alcohol by blocking the effects of these substances and reducing cravings. By binding to opioid receptors in the brain, naltrexone prevents the euphoric effects associated with drug use. The medication is typically administered once daily, and its efficacy in reducing relapse rates has been well established.
Dihydrocodeine Bitartrate is used as the active pharmaceutical ingredient in oral analgesic and antitussive medications. As an opioid derivative, it is prescribed for the relief of moderate to severe pain, particularly in patients who do not respond adequately to other analgesics. It is also utilized as a cough suppressant in certain syrups and tablets.
Dihydrocodeine acts on opioid receptors in the central nervous system to reduce the sensation of pain and suppress the cough reflex. Compared to morphine, it has a milder effect and generally causes less tolerance and dependence; however, it should still be used with caution. The onset of action typically occurs within one hour of oral administration, with effects lasting approximately 4 to 6 hours.
Hydrocodone Bitartrate is used as the primary active ingredient in oral analgesic and antitussive medications. As an opioid derivative, it is commonly prescribed for the relief of moderate to severe pain and for suppressing coughs that are resistant to other treatments. Hydrocodone is often available in combination with acetaminophen or ibuprofen.
Hydrocodone acts on opioid receptors within the central nervous system to reduce pain perception and suppress the cough reflex. Although it is less potent than morphine, it should still be used with caution due to the potential for dependence and tolerance. The onset of action typically occurs within 20 to 30 minutes after oral administration, with effects lasting approximately 4 to 6 hours
Nalbuphine hydrochloride API, a Level 1 knowledge-based product of Soroush Mana Pharmed, is utilized as the primary active component in the manufacture of injectable nalbuphine hydrochloride. Introduced to the U.S. pharmaceutical market and globally in 1963, nalbuphine is a synthetic phenanthrene opioid agonist-antagonist analgesic. Its analgesic potency is essentially equivalent to morphine on a milligram-for-milligram basis. Nalbuphine injections are used both for anesthesia support prior to surgical procedures and as an analgesic for moderate to severe pain.
While the exact mechanism of action of nalbuphine is not fully understood, it is believed to interact with opioid receptors in the central nervous system. Its opioid antagonist effects are thought to result from competitive inhibition at opioid receptors, although other mechanisms may also be involved.
Tramadol Hydrochloride is used as the active pharmaceutical ingredient in both oral and injectable formulations of tramadol. This medication is a centrally acting opioid analgesic, prescribed for the management of moderate to severe pain, including postoperative pain, chronic musculoskeletal pain, and neuropathic pain.
Tramadol alleviates pain by acting on opioid receptors in the brain and inhibiting the reuptake of norepinephrine and serotonin. Compared to other opioids, tramadol has a lower potential for dependence and tolerance; however, there remains a risk of misuse and addiction. The onset of action typically occurs within one hour of oral administration, with effects lasting approximately 4 to 6 hours.